Johnson & Johnson CEO Joaquin Duato says the company has no plans to enter the obesity market, instead focusing on areas such as cancer. He says oncology remains one of J&J's core growth pillars, and highlights dementia as another major challenge for the healthcare industry. Duato also talked about how artificial intelligence could accelerate drug discovery and the development of new medicines. He's on this week's episode of The David Rubenstein Show: Peer to Peer Conversations. This interview was recorded June 16 at The Economic Club of Washington.

<p>Johnson &amp; Johnson CEO Joaquin Duato says the company has no plans to enter the obesity market, instead focusing on areas such as cancer. He says oncology remains one of J&amp;J's core growth pillars, and highlights dementia as another major challenge for the healthcare industry. Duato also talked about how artificial intelligence could accelerate drug discovery and the development of new medicines. He's on this week's episode of The David Rubenstein Show: Peer to Peer Conversations. This interview was recorded June 16 at The Economic Club of Washington.</p>

What makes a great leader? How can leadership be developed into a force for true achievement? The David Rubenstein Show: Peer-to-Peer Conversations explores successful leadership through the personal and professional choices of the most influential people in business. Renowned financier and philanthropist David Rubenstein travels the country talking to leaders to uncover their stories and their path to success. Each episode features an interview with one business leader.

Renowned financier and philanthropist David Rubenstein travels the country talking to leaders to uncover their stories and their path to success

The David Rubenstein Show

Joaquin Duato

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/17aae89d-b412-4f89-be5c-b4dd00e76e6e/transcript